Arshad M. Khanani, MD, MA, FASRS

Arshad M. Khanani, MD, MA, FASRS serves as the Managing Partner, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates, as well as a Clinical Professor at the University of Nevada, Reno School of Medicine.

Articles by Arshad M. Khanani, MD, MA, FASRS

EURETINA 2026: 2-year SPECTRA results and the phase 3 programme for 4D-150 gene therapy in DMO

ByArshad M. Khanani, MD, MA, FASRS,Martin David Harp

October 2nd 2026

At EURETINA 2026, Arshad Khanani, MD, FASRS, reviews 2-year SPECTRA data on 4D-150 gene therapy for DMO and the phase 3 4SIGHT trial comparing it with aflibercept.

ASRS 2026: Arshad M. Khanani, MD, MA, on SOL-1 phase 3 data

ByArshad M. Khanani, MD, MA, FASRS,Martin David Harp

July 17th 2026

Arshad M. Khanani, MD, MA, discusses phase 3 SOL-1 data showing axitinib sustained vision in wet AMD for 9-12 months after 1 dose, outperforming aflibercept 2 mg.

Latest Updated Articles

ASRS 2026: Arshad M. Khanani, MD, MA, on SOL-1 phase 3 data
July 17th 2026

Arshad M. Khanani, MD, MA, FASRS

Articles by Arshad M. Khanani, MD, MA, FASRS

EURETINA 2026: 2-year SPECTRA results and the phase 3 programme for 4D-150 gene therapy in DMO

ASRS 2026: Arshad M. Khanani, MD, MA, on SOL-1 phase 3 data

Latest Updated Articles

Trending on Eye Care Network - Ophthalmology Times

EURETINA 2026: Retinal signs as diagnostic clues to systemic metabolic disease

MOGENRY earns Japan priority review for inherited retinal dystrophies

EURETINA 2026: Predicting geographic atrophy progression with DARC

Aldeyra to appeal FDA rejection of reproxalap as a treatment for dry eye disease

EURETINA 2026: OCT biomarkers that predict, preempt and pinpoint retinal disease